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Abstract
Background: Cladribine or 2-chlorodeoxyadenosine (2-CDA) is a well-known purine nucleoside analog with
particular activity against lymphoproliferative disorders, such as hairy cell leukemia (HCL). Its benefits in multiple
myeloma (MM) remain unclear. Here we report the inhibitory effects of cladribine on MM cell lines (U266,
RPMI8226, MM1.S), and its therapeutic potential in combination with a specific inhibitor of the signal transducer
and activator of transcription 3 (STAT3).
Methods: MTS-based proliferation assays were used to determine cell viability in response to cladribine. Cell cycle
progression was examined by flow cytometry analysis. Cells undergoing apoptosis were evaluated with Annexin V
staining and a specific ELISA to quantitatively measure cytoplasmic histone-associated DNA fragments. Western
blot analyses were performed to determine the protein expression levels and activation.
Results: Cladribine inhibited cell proliferation of MM cells in a dose-dependent manner, although the three MM
cell lines exhibited a remarkably different responsiveness to cladribine. The IC50 of cladribine for U266, RPMI8226,
or MM1.S cells was approximately 2.43, 0.75, or 0.18 μmol/L, respectively. Treatment with cladribine resulted in a
significant G1 arrest in U266 and RPMI8226 cells, but only a minor increase in the G1 phase for MM1.S cells.
Apoptosis assays with Annexin V-FITC/PI double staining indicated that cladribine induced apoptosis of U266 cells
in a dose-dependent manner. Similar results were obtained with an apoptotic-ELISA showing that cladribine
dramatically promoted MM1.S and RPMA8226 cells undergoing apoptosis. On the molecular level, cladribine
induced PARP cleavage and activation of caspase-8 and caspase-3. Meanwhile, treatment with cladribine led to a
remarkable reduction of the phosphorylated STAT3 (P-STAT3), but had little effect on STAT3 protein levels. The
combinations of cladribine and a specific STAT3 inhibitor as compared to either agent alone significantly induced
apoptosis in all three MM cell lines.
Conclusions: Cladribine exhibited inhibitory effects on MM cells in vitro. MM1.S is the only cell line showing
significant response to the clinically achievable concentrations of cladribine-induced apoptosis and inactivation of
STAT3. Our data suggest that MM patients with the features of MM1.S cells may particularly benefit from cladribine
monotherapy, whereas cladribine in combination with STAT3 inhibitor exerts a broader therapeutic potential
against MM.
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Multiple myeloma (MM) is a plasma cell malignancy
characterized by specific genetic and epigenetic changes.
Although many advances have been achieved in recent
studies, MM remains an incurable disease and novel
treatment strategies or agents are urgently needed [1,2].
A number of purine nucleoside analogs are rationally
designed anticancer drugs that exert cytotoxicity via
inhibition of DNA and RNA synthesis, and are currently
used in the treatment of hematologic malignancies [3,4].
Cladribine (also known as 2-chlorodeoxyadenosine, 2-
CDA) is an adenosine deaminase-resistant 2-deoxypur-
ine nucleoside analog which requires phosphorylation by
deoxycytidine kinase. Since this enzyme is mainly
expressed in lymphocytes, cladribine is primarily active
in lymphoid tissues [5]. Cladribine exerts remarkable
activity in hairy cell leukemia (HCL), a chronic B-cell
lymphoproliferative disorder, producing prolonged
complete remissions in most patients [6,7]. Although
cladribine is particularly cytotoxic to malignant B-cells
and T-cells, and is widely used in HCL [8-10], it has not
been approved to treat other lymphoid malignancies.
Increasing evidences suggest that cladribine adminis-
tered in combination with recently approved novel
agents may be a valuable and safe treatment for patients
with chronic lymphocutic leukemia (CLL) [11,12] and
other lymphoid disorders, such as lymphoplasmacytic
lymphoma, marginal zone lymphoma, and mantle cell
lymphoma [13].
Although cladribine has been used for patients with
low grade lymphoma and Waldenstrom’s macroglobuli-
nemia [14], it has only been studied in a limited manner
in patients with MM, without much success [15]. Sev-
eral studies have suggested that since “cladribine has a
narrow spectrum of activity within the B-cell progeny” it
may yet prove to be useful in subsets of patients with
MM [16], because the self-renewing population of MM,
arises at early B-cell precursors [17]. In vitro, the inhibi-
tory effects of cladribine on MM cell lines are conflict-
ing. While some studies observe completely negative
results [18,19], others showing that cladribine has a
marked heterogeneous effect on different MM cell lines
[5] and clearly inhibits proliferation of RPMI8226 cells
at high concentrations [20]. The precise molecular
mechanisms by which MM cells show different respon-
siveness to cladribine remain unclear. It has been
reported that cladribine induces accumulation of DNA
strand breaks, and subsequently activates the tumor
suppressor p53 in lymphocytes [21]. While mutation or
deletion of p53 is rarely detected in untreated MM
[22,23], it is not known whether p53 status in MM cell
lines may influence their sensitivity to cladribine. Recent
studies also suggest that frequent activation of STAT3
signaling provides survival advantage for MM cells
[24-26], and STAT3 may serve as a novel target for the
treatment of hematological tumors, including MM [27].
To date, there is no report indicating whether cladribine
may modulate STAT3 activity in MM cells. Here, we
studied cladribine’s activity against different MM cell
lines with either wild type (WT) or mutant p53, investi-
gated its inhibitory effects on STAT3, and explored the
therapeutic potential of cladribine in combination with a
specific STAT3 inhibitor.
Methods
Reagents and antibodies
Cladribine or 2-chlorodeoxyadenosine (2-CDA) was pur-
chased from Sigma-Aldrich Corp. (St. Louis, MO).
STAT3 inhibitor VI (S3I-201) was obtained from EMD
Chemicals, Inc. (Gibbstown, NJ). Antibodies for western
blot analysis were from following sources: caspase-8
mouse mAb (1C12), caspase-9 polyclonal antibody, cas-
pase-3 rabbit mAb (8G10), Poly (ADP-ribose) polymer-
ase (PARP) rabbit mAb, phospho-STAT3 rabbit mAb
and STAT3 (Cell Signaling Technology, Inc., Beverly,
MA); b-actin mouse mAb (clone AC-75) (Sigma). All
other reagents were purchased from Sigma unless other-
wise specified.
Cells and cell culture
Human MM cell line U266 was kindly provided by Dr.
Lisheng Wang (Institute of Radiology, Academy of Mili-
tary Medical Sciences, Beijing, China). Human MM cell
line RPMI8226 was purchased from the American Type
Culture Collection (ATCC, Manassas, VA). Human MM
cell line MM1.S was kindly provided by Dr. Steven
Rosen (Department of Medicine, Robert H. Lurie
Comprehensive Cancer Center, Northwestern Univer-
s i t y ,C h i c a g o ,I L ) .A l lc e l ll i n e sw e r em a i n t a i n e di n
RPMI1640 cell culture medium supplemented with 10%
fetal bovine serum (FBS) at a 37°C humidified atmo-
sphere containing 95% air and 5% CO2 and were split
twice a week.
Cell proliferation assays
The CellTiter96™ AQ non-radioactive cell prolifera-
tion kit (Promega Corp., Madison, WI) was used to
determine cell viability as we previously described
[28]. In brief, cells were plated onto 96-well plates
with either 0.1 ml complete medium (5% FBS) as
control, or 0.1 ml of the same medium containing a
series of doses of cladribine, and incubated for 72 hrs.
After reading all wells at 490 nm with a micro-plate
reader, the percentages of surviving cells from
each group relative to controls, defined as 100%
survival, were determined by reduction of MTS
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phenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt).
Flow cytometric analysis of cell cycle and apoptosis
Flow cytometric analyses were performed as described
previously [28] to define the cell cycle distribution and
apoptosis for treated and untreated cells. For cell cycle
analysis, cells grown in 100-mm culture dishes were
harvested and fixed with 70% ethanol. Cells were then
stained for total DNA content with a solution contain-
ing 50 μg/ml propidium iodide and 100 μg/ml RNase A
in PBS for 30 min at 37°C. Cell cycle distribution was
analyzed with a FACScan flow cytometer (BD Bios-
ciences, San Jose, CA). For apoptosis analysis, harvested
cells were stained with Annexin V-FITC and propidium
iodide according to the manufacturer’s instruction and
then subjected to the same analyzer.
Quantification of apoptosis
An apoptosis ELISA kit (Roche Diagnostics) was used to
quantitatively measure cytoplasmic histone-associated
DNA fragments (mononucleosomes and oligonucleo-
somes) as previously reported [28].
Western blot analysis
Protein expression levels were determined by western
blot analysis as previously described [28]. Briefly, cells
were lysed in a buffer containing 50 mM Tris, pH 7.4, 50
mM NaCl, 0.5% NP-40, 50 mM NaF, 1 mM Na3VO4, 1
mM phenylmethylsulfonyl fluoride, 25 μg/ml leupeptin,
and 25 μg/ml aprotinin. The protein concentrations of
the total cell lysates were determination by the Coomas-
sie Plus protein assay reagent (Pierce Chemical Co.,
Rockford, IL). Equal amounts of cell lysates were boiled
in Laemmli SDS-sample buffer, resolved by SDS-PAGE,
transferred to nitrocellulose membrane (Bio-Rad Labora-
tories, Hercules, CA), and probed with specific antibodies
as described in the figure legends. After the blots were
incubated with horseradish peroxidase-labeled secondary
antibody (Jackson ImmunoResearch Laboratories, Inc.,
West Grove, PA), the signals were detected using the
enhanced chemiluminescence reagents (Amersham Life
Science, Piscataway, NJ).
Statistical analysis
Statistical analyses of the experimental data were per-
formed using a two-sided Student’s t test. Significance
was set at a P < 0.05.
Results
Cladribine inhibits cell proliferation/survival
of MM cells in vitro
To explore whether cladribine might be a potential
therapeutic agent against MM, we investigated its anti-
proliferative/anti-survival effects on three MM cell lines:
U266, RPMI8226 with mutant p53;a n dM M 1 . Sw h i c h
retains and expresses WT p53 [23]. Although the three
MM cell lines exhibited different sensitivities, cladribine
was able to inhibit proliferation/survival of all cells in a
dose-dependent manner (Figure 1). While U266 was the
least sensitive cell line, MM1.S was the most sensitive one
to cladribine. The IC50s of cladribine for U266,
RPMI8226, MM1.S cells were approximately 2.43, 0.75,
and 0.18 μmol/L, respectively. To determine the molecular
mechanisms by which cladribine inhibited proliferation/
survival of MM cells, we first investigated the effects of
cladribine on cell cycle progression. Both U266 and
RPMI8226 cells with mutant p53 were treated with cladri-
b i n ea tt h es a m ec o n c e n t r a t i o n( 2μmol/L). U266 cells
were collected at different time points (24, 48, or 72 hrs),
and then analyzed with flow cytometry. Treatment with
cladribine gradually increased the percentage of cells in
the G1 phase of the cell cycle and reduced the percentage
of cells in S phase (Figure 2A). Similar results were
obtained in RPMI8226 cells with the treatment of cladri-
bine for 24 hrs (Figure 2B). Cladribine appeared to
increase G2-M phase in U266 cells upon 24 hr-treatment,
it had no significant effect on G2-M phase either in U266
cells with 48 or 72 hr-treatment or in RPMI8226 cells
(Figure 2A &2B). It remains unclear why cladribine
affected G2-M phase in U266 cells only by 24 hr-treat-
ment. MM1.S cells were treated with cladribine at a much
lower concentration (0.5 μmol/L) for 24 hrs. Cladribine
induced a minor increase in G1 phase, decreased the per-
centage cells in S phase, and had no effect on G2-M phase
in MM1.S cells (Figure 2C). Although our cell proliferation
assays indicated that the IC50 of cladribine was much
lower for MM1.S cells than the IC50s for U266 and
RPMI8226 cells (Figure 1), it appeared G1 arrest-induced
by cladribine in MM1.S cells was not as profound as that
we observed in the other two cell lines (Figure 2). It is
likely that the potent anti-proliferative/anti-survival effects
of cladribine on MM1.S cells may be mainly due to its
strong capability to induce apoptosis as we discovered in
the following studies (Figures 3 &4). Collectively, our data
suggest that induction of cell cycle G1 arrest contributes to
cladribine-mediated growth inhibition in MM cells.
Cladribine induces apoptosis in MM cells
We next studied whether cladribine might also induce
apoptosis in these MM cells, using two different meth-
ods. U266 cells were double-stained with Annexin V
and propidium iodide, and then analyzed by a FACScan
flow cytometer. These studies showed that cladribine
induced apoptosis in U266 cells in a dose-dependent
manner. The percentages of apoptotic cells evidenced by
Annexin V-positive staining were 5%, 15%, 21%,
and 33% when U266 cells were untreated or treated
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When an ELISA methodology was used to quantify
apoptosis in RPMI8226 and MM1.S treated with cla-
dribine, a dose-dependent increase in apoptosis was
seen in both RPMI8226 and MM1.S cells (Figure 3B
&3C). Consistent with the cell proliferation data
(Figure 1), MM1.S was more sensitive to cladribine
than RPMI8226 cells. To explore whether cladribine
induced apoptosis through caspase-dependent mechan-
ism, we carried out western blot assays to examine
activation of caspases and PARP cleavage. In U266
cells, we were able to observe caspase-3 and caspase-8
activation and PARP cleavage only with cladribine at a
higher concentration (10 μmol/L), however, it had no
significant effect on caspase-9 activation (Figure 4A).
Similar results were obtained in RPMI8226 cells treated
with 1 μmol/L of cladribine for 48 hrs (Figure 4B). In
contrast, treatment with cladribine at 0.2 μmol/L dra-
matically induced activation of caspase-3, -8, and -9 and
PARP cleavage in a time-dependent manner in MM1.S
(Figure 4C). Consistent with previous data derived from
the apoptotic-ELISA (Figure 3B &3C), the lowest con-
centration of cladribine induced strongest activation of
caspases and PARP cleavage in MM1.S cells (Figure 4).
Taken together, our studies indicate that caspase-
dependent apoptosis contributes to cladribine-mediated
anti-proliferation/anti-survival effects on MM cells.
Among the three MM cell lines tested, MM1.S is the
most sensitive one to cladribine-induced apoptosis.
Cladribine inactivates STAT3 signaling in MM cells
It has been reported that constitutive activation of
STAT3 is common in many human and murine cancer
cells, and leads to cellular transformation [29,30]. Since
aberrant activation of STAT3 plays a critical role in the
development of human cancers, including MM [27],
numerous studies have tried to identify novel anticancer
strategies/agents targeting STAT3 [27,31]. To test
whether cladribine’s inhibitory activity against MM cells
is due to STAT3 inactivation, we performed western
blot analysis to determine the phosphorylation status of
STAT3 in cladrabine-treated MM cells. In all three MM
cell lines, cladribine significantly decreased the phos-
pho-STAT3 (P-STAT3) levels in a dose-dependent
manner, but had no effect on the total STAT3 protein
levels (Figure 5). As with our cell proliferation (Figure 1)
and apoptosis data (Figures 3 &4), treatment with low
doses of cladribine (0.2 μmol/L) was as effective in
reducing P-STAT3 in MM1.S cells (Figure 5C) as high
doses were when applied to U266 (2 μmol/L) and
RPMA8226 (1 μmol/L) cells (Figure 5A &5B). These
data suggest that cladribine-induced growth inhibition
and apoptosis in MM cells may be associated with its
inactivation of STAT3.
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Figure 1 Cladribine inhibits proliferation/survival of MM cells.
Human MM cells (1 × 10
4 cells/well) were plated onto 96-well
plates with complete culture medium (RPMI1640, 10% FBS). After 24
hrs, the medium was replaced with fresh medium (0.5% FBS) or
same medium containing indicated concentrations of cladribine for
another 72 hrs. The percentages of surviving cells as compared to
controls, defined as 100% survival, were determined by reduction of
MTS. Data shows the representative of three independent
experiments. Bars, SD. A, U266; B, RPMI8226; C, MM1.S
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Figure 2 Cladribine induces cell cycle G1 arrest in MM cells. A, U266 cells were cultured with RPMI1640 (0.5% FBS) in the absence or
presence of cladribine (2 μmol/L) for 24, 48, or 72 hrs. Cells were harvested and subjected to flow cytometry analysis of cell cycle distribution.
Data shows the representative of three independent experiments. B&C , RPMI8226 (B) and MM1.S (C) cells cultured with RPMI1640 (0.5% FBS) in
the absence or presence of cladribine for 24 hrs were harvested and subjected to flow cytometry analysis of cell cycle distribution. Data shows
the representative of three independent experiments.
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Figure 3 Cladribine induces apoptosis in MM cells. A, U266 cells were cultured with RPMI1640 (0.5% FBS) in the absence or presence of
indicated concentrations of cladribine for 24 hrs. Cells were harvested and double-stained with Annexin V/PI, and then subjected to FACScan.
The percentages of Annexin V-positive staining cells, indicative of apoptosis, were shown. B&C , RPMI8226 and MM1.S cells were cultured with
RPMI1640 (0.5% FBS) in the absence or presence of indicated concentrations of cladribine for 24 hrs. Cells were collected and subjected to a
specific apoptotic-ELISA. Bars, SD.
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inhibitor, significantly promote MM cells undergoing
apoptosis
Since STAT3 activation is important in the development
of human cancers, including MM [27], and cladribine
was able to inhibit STAT3 in MM cells (Figure 5), we
hypothesized that the combinations of cladribine and a
specific STAT3 inhibitor might exhibit super activity in
inducing apoptosis in MM cells. S3I-201, which selec-
tively inhibits STAT3 DNA-binding activity [32], was
chosen to test this hypothesis. It has been shown that
treatment with 30 μmol/L of S3I-201 for 48 hrs induces
significant apoptosis in human breast cancer cell line
MDA-MB-435, which harbors constitutive active STAT3
[32]. S3I-201 with 5 μmol/L was used in the following
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Figure 4 Cladribine induces activation of caspase-3, -8, -9 and
PARP cleavage in MM cells. A, U266 cells were untreated or
treated with indicated concentrations of cladribine for 24 hrs. B&C ,
RPMI8226 or MM1.S cells were untreated or treated with cladribine
(1 μmol/L or 0.2 μmol/L, respectively) for 16, 24, or 48 hrs. Cells
were collected and subjected to western blot analyses with specific
antibodies directed against caspase-3 (Casp-3), caspase-8 (Casp-8),
caspase-9 (Casp-9), PARP, or b-actin.
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Figure 5 Cladribine inactivates STAT3 in MM cells in a dose-
dependent manner. U266 (A), RPMI8226 (B), and MM1.S (C) cells
untreated or treated with indicated concentrations of cladribine for
24 hrs collected and subjected to western blot analyses with
specific antibodies directed against P-STAT3, STAT3, or b-actin.
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tosis in all the three MM cell lines (Figure 6). In contrast,
different concentrations of cladribine were used in the
combinational studies: 2 μmol/L for U266 cells, 1 μmol/L
for RPMI8226 cells, and 0.2 μmol/L for MM1.S cells,
because treatment with cladribine at this concentration
for 24 hrs did decrease P-STAT3 levels (Figure 5),
but had no significant induction of caspase activation
and PARP cleavage for each of the three MM cell lines
(Figure 4). As expected, the combinations of cladribine
and S3I-201 induced strong activation of caspase-3 and
-8, and PARP cleavage in all three MM cell lines
(Figure 6A). Furthermore, apoptotic-ELISA demon-
strated that their combinations, as compared to either
agent alone, significantly promoted MM cells undergoing
apoptosis (Figure 6B, P <0 . 0 0 2 ,P < 0.0007, P <0 . 0 0 2f o r
U266, RPMI8226, MM1.S, respectively).
Discussion
Although cladribine inhibited cell proliferation and
induced apoptosis in all three MM cell lines tested, we
used a wide range of concentrations of cladribine.
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Figure 6 The combinations of cladribine and S3I-201 significantly induce apoptosis in MM cells. MM cells were untreated or treated
with either S3I-201 (5 μmol/L), or cladribine (2 μmol/L for U266, 1 μmol/L for RPMI8226, 0.2 μmol/L for MM1.S) alone, or the combinations
of S3I-201 and cladribine for 24 hrs. A, Cells were collected and subjected to western blot analyses with specific antibodies directed against
caspase-3 (Casp-3), caspase-8 (Casp-8), PARP, or b-actin. B, Cells were collected and subjected to a specific apoptotic-ELISA. Bars,S D .P values
vs single agent.
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2-hr bolus at a dose of 0.14 mg/kg, the mean peak
plasma concentration of cladribine reaches 198 nmol/L
and falls to 22.5 nmol/L within 6-hr [33,34]. The MM1.
S cell line was the only one showing significant growth
inhibition and apoptosis-induced by cladribine within
this concentration range (Figures 1C, 3C, &4C). While
our studies are consistent with a previous report indicat-
ing that cladribine has a heterogeneous effect on differ-
ent MM cell lines [5], they suggest that cladribine may
be useful to treat a subset of MM patients whose cells
share similarities with MM1.S cells, which retain and
express WT p53 [23]. In addition, like other clinically
important nucleoside analogs, cladribine’s effectiveness
may be critically determined by the expression levels of
deoxycytidine kinase (DCK), as this kinase is required to
phosphorylate cladribine, and subsequently convert the
inactive pro-drug into its active form [21]. We are cur-
rently testing whether cladribine may activate the tumor
suppressor p53 in MM1.S cells, and whether or not this
line expresses higher levels of DCK than U266 and
RPMI8226 cells. Since cladribine at the clinically rele-
vant concentrations dramatically reduced the levels of
P-STAT3 in MM1.S cells (Figure 5C), this might serve
as an in vitro screen for identifying potential cladribine
candidates. These findings also suggest that cladribine-
resistance may be attributed, in part, to a hyperactive
STAT3 signaling pathway, which frequently occurs in
MM [24-26]. In this report, we have focused our studies
on modulation of STAT3 activity. Our data showed that
the combinations of caldribine and S3I-201, a specific
STAT3 inhibitor, indeed significantly induced apoptosis
in all three MM cell lines (Figure 6).
Recent advances in identifying novel therapeutics
against MM have provided new hope for this incurable
disease. The inhibitors of histone deacetylase (HDAC)
are promising agents for treatment of MM [35,36]. Our
recent studies indicate that a class I HDAC inhibitor
(HDACi), SNDX-275 exhibits strong anti-MM activities
via enhanced DNA damage response and induction of
apoptosis [28]. Although two HDACis, LBH589 and
AR-42, have been shown to reduce STAT3 levels in
human lung cancer cells and malignant mast cell dis-
ease, respectively [37,38], the effects of SNDX-275 on
STAT3 activation and/or expression in MM cells remain
unknow. It is not clear if SNDX-275 could reverse the
cladribine resistant phenotype. It would be interesting
and in clinical relevance to test the combinational
activities of cladribine and SNDX-275 in MM.
It has been reported that the insulin-like growth fac-
tor-1 (IGF-1) and interleukin-6 (IL-6) are two major
MM growth factors promoting cell proliferation and
survival, and play a critical role in MM development
[39,40]. Strategies targeting IGF-1 receptor (IGF-1R) -
blocking antibodies and small molecule inhibitors -
show very encouraging preclinical results against
MM cells [41], and both strategies are now in clinical
trials [42]. IGF-1 and IL-6 binds their specific receptors
and subsequently result in activation of several signal
transduction pathways [35], including the JAK/STAT3,
PI-3K/Akt, Ras/MAPK, NF-Ba n db-catennin pathway.
The PI-3K/Akt signaling is a well-known cell survival
pathway, and its activation often leads to resistance
to therapeutic agents in cancer treatment [43,44].
Currently, it is unclear whether the autocrine or para-
crine IGF-1/IGF-1R loop in MM and through which
downstream signaling pathways may also contribute to
cladribine-resistance as we observed in U266 and
RPMI8226 cells.
Conclusions
Cladribine-induced growth inhibition and apoptosis in
MM cells correlated with its ability to inactivate STAT3.
Cladribine in combination with S3I-201, a specific
STAT3 inhibitor, resulted in significant apoptosis in all
three MM cell lines as compared to either agent alone.
Although cladribine as a single agent seems active in
MM cells with WT p53, our studies suggest that the
combinational regimens consisting of cladribine and
STAT3 inhibitors may be more promising for MM
patients.
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